Michael Green (January 20, 1954 – February 10, 2023) was an American molecular biologist and cell biologist at the University of Massachusetts Medical School, where he was the chair of the Department of Molecular, Cell and Cancer Biology, director of the UMass Cancer Center, and a Howard Hughes Medical Institute investigator.[1][2] Green was a member of the National Academy of Sciences and the National Academy of Medicine.[3][4]
Michael Green | |
|---|---|
| Born | January 20, 1954 Philadelphia, Pennsylvania, U.S. |
| Died | February 10, 2023 (aged 69) |
| Alma mater | University of Wisconsin–Madison, Washington University in St. Louis |
| Scientific career | |
| Fields | Cell biology, molecular biology |
| Institutions | University of Massachusetts Medical School |
| Doctoral advisor | Robert G. Roeder |
| Notable students | Phil Zamore |
Education and academic career
editGreen received his bachelor's degree in biochemistry from the University of Wisconsin–Madison.[1][5] He then went on to Washington University School of Medicine, from which he graduated in 1981 with his M.D. and Ph.D. in biochemistry under the supervision of Robert G. Roeder.[1][5] He worked as a postdoctoral fellow with Thomas Maniatis, then at Harvard University, before joining the faculty there in 1984. He moved from Harvard to the University of Massachusetts Medical School in 1990 and remained there until his death in 2023. He was the chair of the Department of Molecular, Cell and Cancer Biology and was named the director of the UMass Cancer Center in 2015.[1][2]
Green became a Howard Hughes Medical Institute investigator in 1994.[5] He was elected to the National Academy of Sciences in 2014[3] and to the National Academy of Medicine in 2015.[4]
Green was a co-founder of a Cambridge, Massachusetts-based biotechnology company called Fulcrum Therapeutics.[6]
Research
editResearch in Green's laboratory focused on gene regulation, particularly on the regulation of gene transcription and of RNA splicing. The group also studies the effects of regulatory patterns on the behavior of cancer cells, using genome-wide RNA interference screens to identify genes involved in cell proliferation or apoptosis in the context of oncogenic mutations.[1][5] In 2014, Green began studying the rare genetic disease Rett syndrome.[7]
Death
editReferences
edit- ^ a b c d e "Michael Green". UMass Profiles. Retrieved 12 April 2017.
- ^ a b "Michael Green appointed director of UMass Cancer Center". UMass Med Now. 29 April 2015. Retrieved 12 April 2017.
- ^ a b Larson, Lisa M. (30 April 2014). "Michael Green elected to National Academy of Sciences". UMass Med Now. Retrieved 12 April 2017.
- ^ a b Larson, Lisa M. (19 October 2015). "Michael Green elected to National Academy of Medicine". University of Massachusetts News. Retrieved 12 April 2017.
- ^ a b c d "Michael Green". Howard Hughes Medical Institute. Retrieved 12 April 2017.
- ^ "Founders". Fulcrum Therapeutics. Retrieved 12 April 2017.
- ^ Larson, Lisa M.; Goodchild, Bryan (7 May 2014). "UMMS scientist aiding a mother's quest for rare disease cure". UMass Med Now. Retrieved 12 April 2017.
- ^ Michael R. Green, MD, PhD
- ^ Tehan, Isabel (13 February 2023). "UMass Chan professor, vice provost for research dies unexpectedly". Worcester Business Journal. Retrieved 13 February 2023.